+

WO2023033017A1 - Procédé pour la production de ganirélix ou d'un sel de celui-ci - Google Patents

Procédé pour la production de ganirélix ou d'un sel de celui-ci Download PDF

Info

Publication number
WO2023033017A1
WO2023033017A1 PCT/JP2022/032700 JP2022032700W WO2023033017A1 WO 2023033017 A1 WO2023033017 A1 WO 2023033017A1 JP 2022032700 W JP2022032700 W JP 2022032700W WO 2023033017 A1 WO2023033017 A1 WO 2023033017A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
ring
amino acid
amino
hydrogen atom
Prior art date
Application number
PCT/JP2022/032700
Other languages
English (en)
Japanese (ja)
Inventor
真也 矢野
卓 松本
Original Assignee
積水メディカル株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 積水メディカル株式会社 filed Critical 積水メディカル株式会社
Publication of WO2023033017A1 publication Critical patent/WO2023033017A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to a method for producing a gonadotropin antagonist Ganirelix or a salt thereof.
  • Ganirelix is a gonadotropin antagonist and is marketed as an anti-premature ovulatory drug under controlled ovarian stimulation.
  • Ganirelix is a decapeptide drug having diethylhomoarginine residues at the 3rd and 5th positions from the C-terminus, and is produced by a solid-phase peptide synthesis method (Patent Documents 1 and 2, Non-Patent Document 1).
  • the solid-phase peptide synthesis method is preferable for small amounts of reagents, but it is not suitable for mass production such as supply as pharmaceuticals. This is because the solid-phase synthesis is a heterogeneous reaction system, the mixing efficiency is low, and the reaction rate is slow. Furthermore, since the peptide cannot be purified during the reaction, it is necessary to use a large excess of 3 to 4 equivalents of amino acids and reagents to be extended for the purpose of quantitative reaction. On the other hand, according to the liquid-phase peptide synthesis method, it is a homogeneous reaction system, and it is possible to reduce the amount of reagents used.
  • the amino acid or the like bound to the carrier is dissolved in the organic layer, and unnecessary components such as surplus raw material amino acids used in the peptide elongation reaction and its By dissolving in the aqueous layer the decomposition products and compounds produced as by-products when the protective groups of the starting amino acids are deprotected, there is an advantage that the amino acids bound to the carrier can be simply purified by liquid-liquid separation. Furthermore, there is also the advantage that crude purification of the peptide is possible even in a carrier-bound state.
  • amino acid amide refers to a structure in which the C-terminal carboxy group (--COOH) of an amino acid is replaced by an amide group (--CONH 2 ).
  • amide group refers to a structure in which the C-terminal carboxyl group of a peptide is an amide group.
  • an object of the present invention is to provide a new method for producing Ganirelix by a liquid-phase peptide synthesis method.
  • the present invention provides the following inventions [1] to [11].
  • [1] A method for producing Ganirelix or a salt thereof by a liquid-phase peptide synthesis method, wherein the following formulas (1) to (3) are used as starting materials for the condensation reaction of the 3rd and 5th diethylhomoarginine residues from the C-terminus.
  • a method for producing ganirelix or a salt thereof using one or more compounds of the group represented by and a carrier for liquid-phase peptide synthesis [2] The production method according to [1], characterized by including the following steps a to c. a. a step of condensing an amino acid, peptide, amino acid amide or peptide amide bound to a carrier for liquid phase peptide synthesis with an amino acid or peptide having a protected amino group in a solvent containing an organic solvent; b.
  • the amino acid sequence of the Ganirelix or its salt is D-AlaNH 2 , Pro, hArg(Et) 2 , Leu, D-hArg(Et) 2 , Tyr, Ser, D-3-pyridyl Ala from the C-terminal side.
  • the water-soluble amine is hydroxylamine, amidosulfuric acid, hydroxylamine-O-sulfonic acid, hydroxylamine-O-phosphonic acid, or an alkyl group, alkenyl group, cycloalkyl group, cycloalkenyl group, aryl group, aralkyl primary, secondary or tertiary amines having one or more selected from groups and heterocyclic groups, wherein a hydroxy group, an ether bond, an alkoxy group, a sulfonyl group, a sulfonic acid group, a sulfate group, and a phosphoric acid group, the production method according to [7], which is an amine optionally having one or more substituents.
  • the dibenzofulvene trapping agent is a mercapto compound having an alkyl group of 1 to 10 carbon atoms and is selected from carboxylic acid, alkali metal salt of carboxylic acid, sulfonic acid, or alkali metal salt of sulfonic acid.
  • the production method according to any one of [1] to [10], wherein the carrier for liquid-phase peptide synthesis is a compound represented by the following formula (I).
  • Ring A represents a C4-20 aromatic ring which may contain heteroatoms and may be polycyclic;
  • R 11 is a hydrogen atom, or when ring A is a benzene ring and Rb is a group represented by the following formula (b), together with R 13 represents a single bond, and ring A and may form a fluorene ring together with ring B, or may form a xanthene ring together with ring A and ring B via an oxygen atom;
  • p R 12 are each independently an aliphatic hydrocarbon group, an aliphatic hydrocarbon group substituted with an aliphatic hydrocarbon group via an oxygen atom, or an
  • R 16 represents a linear or branched alkylene group having 6 to 16 carbon atoms
  • R 17 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms.
  • A represents either a silyl group or an alkyl group to which a silyloxy group is attached; p represents an integer of 1 to 4; Ring A is, in addition to p X 1 R 12 , a halogen atom, a C1-6 alkyl group optionally substituted with a halogen atom, and a C1-6 alkoxy group optionally substituted with a halogen atom It may have a substituent selected from the group consisting of; Ra represents a hydrogen atom or an aromatic ring optionally substituted with a halogen atom; Rb represents a hydrogen atom, an aromatic ring optionally substituted with a halogen atom, or formula (b);
  • R 16 represents a linear or branched alkylene group having 6 to 16 carbon atoms
  • R 17 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms
  • A represents either a silyl group or an alkyl group to which a silyloxy group is attached
  • R 13 represents a hydrogen atom, represents a single bond together with R 11 to form a fluorene ring together with ring A and ring B, or forms a xanthene ring together with ring A and ring B through an oxygen atom.
  • Ring B in addition to q X 2 R 14 , further comprises a halogen atom, a C1-6 alkyl group optionally substituted with a halogen atom, and a C1-6 alkoxy group optionally substituted with a halogen atom may have a substituent selected from the group consisting of ) represents a group represented by; Y represents a hydroxy group, a thiol group, NHR 20 (R 20 represents a hydrogen atom, an alkyl group or an aralkyl group) or a halogen atom. ]
  • Ganirelix or a salt thereof is produced by the method using the protected form of diethylhomoarginine of the present invention, the liquid-liquid separation after the condensation reaction is facilitated, and Ganirelix or a salt thereof can be industrially produced advantageously.
  • Ganirelix the target compound of the present invention
  • is a gonadotropin antagonist and is marketed as an anti-premature ovulatory agent under controlled ovarian stimulation.
  • the amino acid residues constituting the decapeptide structure are, from the C-terminal side, D-AlaNH 2 , Pro, hArg(Et) 2 , Leu, D-hArg(Et) 2 , Tyr, Ser, D- It may be abbreviated as 3-pyridyl Ala, Dp-chloroPhe, and D-naphthyl Ala.
  • the method for producing Ganirelix or a salt thereof of the present invention is a method for producing Ganirelix or a salt thereof by a liquid-phase peptide synthesis method, wherein the following are used as starting materials for the condensation reaction of the 3rd and 5th diethylhomoarginine residues from the C-terminus: Formulas (1) to (3)
  • R 1 and R 2 represent Boc, Cbz, Troc, Alloc, Trt, Mmt, Teoc, Phth, SES, or ivDde, and R 3 represents an amino protecting group
  • R 1 and R 2 are protecting groups, Boc (tert-butoxycarbonyl), Cbz (benzyloxycarbonyl), Troc (2,2,2-trichloroethoxycarbonyl) or Alloc (allyloxycarbonyl), Trt (trityl) , Mmt (4-monomethoxytrityl), Teoc (2-(trimethylsilyl)ethoxycarbonyl), Phth (phthaloyl), SES ((2-trimethylsilyl)-ethanesulfonyl), ivDde (1-(4,4-dimethyl-2 , 6-dioxocyclohex-1-ylidene)-3-methylbutyl).
  • R 3 represents an amino protecting group.
  • the amino-protecting group includes Fmoc (9-fluorenylmethyloxycarbonyl), Boc, Cbz, etc. Among them, Fmoc and Cbz are preferred, and Fmoc, which can be deprotected under basic conditions, is more preferred.
  • R 1 , R 2 and R 3 are preferably orthogonal protecting groups. That is, preferably the deprotection conditions for R 1 and R 2 do not affect R 3 and the deprotection conditions for R 3 do not affect R 1 and R 2 . Particularly preferred are compounds in which R 1 and R 2 are Boc and R 3 is Fmoc.
  • the structures represented by formulas (1) to (3) are E/Z isomers or imino/amino isomers, and the compound may be a mixture of these isomers.
  • the compounds represented by the above formulas (1) to (3) are, for example, ⁇ -amino-protected diethylhomoarginine, or a conjugate of this with a carrier for liquid-phase peptide synthesis, di-tert-butyl dicarbonate, N- It can be produced by reacting an amino-protecting agent such as a Boc agent such as tert-butoxycarbonylimidazole.
  • an amino-protecting agent such as a Boc agent such as tert-butoxycarbonylimidazole.
  • this Boc-forming reaction is preferably carried out in a solvent in the presence of a base.
  • the base may be an organic base such as pyridine, triethylamine, DMAP (4-dimethylaminopyridine), N-methylimidazole, or a mixed organic base thereof, and an inorganic base such as sodium carbonate, potassium carbonate, sodium hydrogen carbonate, sodium hydroxide.
  • a base may be used.
  • the amount of the base to be added is 0.1 to 30 equivalents, preferably 1 to 20 equivalents relative to the arginine derivative, but is not limited thereto.
  • Reaction solvents include water, THF (tetrahydrofuran), 2-methylTHF, 1,4-dioxane, toluene, DMF (N,N-dimethylformamide), acetonitrile, dichloromethane, chloroform, methanol, ethanol, or mixed solvents thereof. is used.
  • the reaction is preferably carried out at 0° C. to 40° C. for 1 to 24 hours.
  • Such a carrier for liquid-phase peptide synthesis may be a carrier that protects functional groups of amino acids, peptides, amino acid amides or peptide amides (amino acids, etc.) and solubilizes the protected amino acids, etc. in an organic solvent.
  • a carrier for liquid-phase peptide synthesis may be a carrier that protects functional groups of amino acids, peptides, amino acid amides or peptide amides (amino acids, etc.) and solubilizes the protected amino acids, etc. in an organic solvent.
  • the compounds described in Patent Documents 3 to 18 can be used.
  • Specific examples of such carriers for liquid-phase peptide synthesis include compounds represented by the following formula (I).
  • Ring A represents a C4-20 aromatic ring which may contain heteroatoms and may be polycyclic;
  • R 11 is a hydrogen atom, or when ring A is a benzene ring and Rb is a group represented by the following formula (b), together with R 13 represents a single bond, and ring A and may form a fluorene ring together with ring B, or may form a xanthene ring together with ring A and ring B via an oxygen atom;
  • p R 12 are each independently an aliphatic hydrocarbon group, an aliphatic hydrocarbon group substituted with an aliphatic hydrocarbon group via an oxygen atom, or an
  • R 16 represents a linear or branched alkylene group having 6 to 16 carbon atoms
  • R 17 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms.
  • A represents either a silyl group or an alkyl group to which a silyloxy group is attached; p represents an integer of 1 to 4; Ring A is, in addition to p X 1 R 12 , a halogen atom, a C1-6 alkyl group optionally substituted with a halogen atom, and a C1-6 alkoxy group optionally substituted with a halogen atom It may have a substituent selected from the group consisting of; Ra represents a hydrogen atom or an aromatic ring optionally substituted with a halogen atom; Rb represents a hydrogen atom, an aromatic ring optionally substituted with a halogen atom, or a group represented by formula (b);
  • R 16 represents a linear or branched alkylene group having 6 to 16 carbon atoms
  • R 17 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms
  • A represents either a silyl group or an alkyl group to which a silyloxy group is attached
  • R 13 represents a hydrogen atom, represents a single bond together with R 11 to form a fluorene ring together with ring A and ring B, or forms a xanthene ring together with ring A and ring B through an oxygen atom.
  • Ring B in addition to q X 2 R 14 , further comprises a halogen atom, a C1-6 alkyl group optionally substituted with a halogen atom, and a C1-6 alkoxy group optionally substituted with a halogen atom It may have a substituent selected from the group consisting of; Y represents a hydroxy group, a thiol group, NHR 20 (R 20 represents a hydrogen atom, an alkyl group or an aralkyl group) or a halogen atom. ]
  • Ring A in formula (I) represents a C4-20 aromatic ring which may contain a heteroatom and may be monocyclic or polycyclic.
  • the aromatic ring includes a C6-20 aromatic hydrocarbon ring and a C4-10 aromatic heterocyclic ring.
  • Specific C6-20 aromatic hydrocarbon rings include benzene ring, naphthalene ring, anthracene ring, phenanthrene ring, triphenylene ring, tetracene ring, indane ring, indene ring, fluorene ring, biphenyl ring, 1,1′- A binaphthalene ring and the like can be mentioned.
  • the C4-10 aromatic heterocycle is preferably a 5- to 10-membered aromatic heterocycle containing 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur atoms, specifically , pyrrole ring, furan ring, thiophene ring, indole ring, benzofuran ring, benzothiophene ring, carbazole ring, pyrazole ring, indazole ring, imidazole ring, pyridine ring, quinoline ring, isoquinoline ring and the like.
  • a 5- to 8-membered aromatic heterocyclic ring containing 1 to 3 atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom as a heteroatom is preferable, a pyrrole ring, a furan ring, a thiophene ring, an indole ring, A benzofuran ring, a benzothiophene ring, a carbazole ring, a pyrazole ring, and an indazole ring are more preferred.
  • R 11 represents a hydrogen atom, or represents a single bond together with R 13 when ring A is a benzene ring and Rb is a group represented by the formula (b); and ring B together to form a fluorene ring, or may form a xanthene ring together with ring A and ring B via an oxygen atom.
  • the ring which may be formed by R 11 and R 13 together is preferably a fluorene ring or a xanthene ring.
  • R 15 represents a hydrogen atom, an alkyl group or an aralkyl group
  • R 15 is preferably a hydrogen atom, a C1-10 alkyl group or a C7-20 aralkyl group.
  • Alkyl groups include linear or branched C1- Ten alkyl groups are mentioned.
  • Aralkyl groups include C7-16 aralkyl groups such as benzyl, 1-phenylethyl, 2-phenylethyl, 1-phenylpropyl, naphthylmethyl and 1-naphthylethyl groups.
  • p R 12 are each independently an aliphatic hydrocarbon group, an aliphatic hydrocarbon group substituted with an aliphatic hydrocarbon group via an oxygen atom, or an organic indicating a group;
  • R 16 represents a linear or branched alkylene group having 6 to 16 carbon atoms
  • R 17 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms
  • A represents either a silyl group or an alkyl group to which a silyloxy group is attached;
  • p represents an integer of 1-4.
  • an organic group having an aliphatic hydrocarbon group is a monovalent organic group having an aliphatic hydrocarbon group in its molecular structure.
  • the site of the aliphatic hydrocarbon group in the organic group having the aliphatic hydrocarbon group is not particularly limited, and may be present at the terminal or at any other site.
  • the aliphatic hydrocarbon group present in the organic group is a linear, branched or cyclic saturated or unsaturated aliphatic hydrocarbon group.
  • a hydrogen group is preferred, a C5-50 aliphatic hydrocarbon group is more preferred, and a C8-30 aliphatic hydrocarbon group is even more preferred.
  • the aliphatic hydrocarbon group examples include an alkyl group, a cycloalkyl group, an alkenyl group, an alkynyl group and the like, with alkyl groups, cycloalkyl groups and alkenyl groups being particularly preferred, and alkyl groups being more preferred.
  • a C5-30 linear or branched alkyl group, a C3-8 cycloalkyl group, a C5-30 linear or branched alkenyl group are preferred, and a C5-30 linear or branched alkyl group.
  • a C3-8 cycloalkyl group is more preferred, a C5-30 linear or branched alkyl group is more preferred, and a C8-30 linear or branched alkyl group is even more preferred.
  • alkyl group examples include alkyl groups having 1 to 30 carbon atoms, such as methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group and pentyl group.
  • branched alkyl group includes 2,3-dihydrophytyl group and 3,7,11-trimethyldodecyl group.
  • X 1 R 12 includes 2,2,4,8,10,10-hexamethyl-5-dodecanoic acid amide.
  • the alkenyl group includes monovalent groups such as vinyl group, 1-propenyl group, allyl group, isopropenyl group, butenyl group, isobutenyl group and oleyl group, and divalent groups derived therefrom.
  • the alkynyl group includes an ethynyl group, a propargyl group, a 1-propynyl group and the like.
  • the above aliphatic hydrocarbon group may be substituted with an aliphatic hydrocarbon group via an oxygen atom.
  • the aliphatic hydrocarbon group capable of substituting an oxygen atom on the aliphatic hydrocarbon group include straight-chain or branched-chain alkoxy groups having 1 to 20 carbon atoms, alkenyloxy groups having 2 to 20 carbon atoms, and 3 carbon atoms. monovalent groups such as cycloalkyloxy groups of up to 6, divalent groups derived therefrom, and the like. Further, it may have a repeating structure in which an aliphatic hydrocarbon group substituted with an aliphatic hydrocarbon group through an oxygen atom is further substituted with an aliphatic hydrocarbon group through an oxygen atom.
  • R 12 12-docosyloxy-1-dodecyl group, 3,4,5-tris(octadecyloxy)benzyl group, 2,2,2-tris(octadecyloxymethyl)ethyl group, 3,4, 5-tris(octadecyloxy)cyclohexylmethyl group and the like.
  • the above aliphatic hydrocarbon group may be substituted with an organic group represented by formula (a).
  • R 16 represents a linear or branched alkylene group having 6 to 16 carbon atoms
  • X 3 is an oxygen atom or —C( ⁇ O)NR 17 —(R 17 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms
  • A represents a silyl group or an alkyl group to which a silyloxy group is bonded
  • the silyl group is preferably a silyl group substituted by three groups selected from linear or branched alkyl groups having 1 to 6 carbon atoms and aryl groups which may have a substituent.
  • examples of the aryl group which may have a substituent include a phenyl group and a naphthyl group.
  • a preferred silyl group is a silyl group substituted with three linear or branched alkyl groups having 1 to 6 carbon atoms, more preferably three linear or branched alkyl groups having 1 to 4 carbon atoms. It is a substituted silyl group.
  • the three alkyl groups or aryl groups substituting on the silyl group may be the same or different.
  • one silyloxy group substituted by three selected from linear or branched alkyl groups having 1 to 6 carbon atoms and aryl groups which may have substituents is used as the alkyl group to which the silyloxy group is bonded.
  • a linear or branched alkyl group having 1 to 13 carbon atoms with ⁇ 3 bonds is preferred.
  • a preferred silyloxy group is a silyloxy group substituted with three linear or branched alkyl groups having 1 to 6 carbon atoms, more preferably three linear or branched alkyl groups having 1 to 4 carbon atoms. It is a substituted silyloxy group.
  • the three alkyl groups or aryl groups substituted on the silyloxy group may be the same or different.
  • the linear or branched alkyl group having 1 to 13 carbon atoms is preferably branched, and more preferably has a quaternary carbon atom.
  • p represents an integer of 1 to 4.
  • p is preferably 1-3, more preferably 1-2.
  • Ring A is, in addition to p X 1 R 12 , a halogen atom, a C1-6 alkyl group optionally substituted with a halogen atom, and a C1-6 alkoxy group optionally substituted with a halogen atom may have a substituent selected from the group consisting of Halogen atoms include chlorine, fluorine, bromine and iodine atoms.
  • the C1-6 alkyl group optionally substituted with a halogen atom includes a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, a pentyl group and a hexyl group. , a dichloromethyl group, a trichloromethyl group, a trifluoromethyl group, and the like.
  • the C1-6 alkoxy group optionally substituted with a halogen atom includes a methoxy group, an ethoxy group, a propyloxy group, an isopropyloxy group, a butyloxy group, an isobutyloxy group, a sec-butyloxy group, a tert-butyloxy group, and a trichloromethoxy group. groups, trifluoromethoxy groups, and the like.
  • Ra represents a hydrogen atom or an aromatic ring optionally substituted with a halogen atom.
  • the aromatic ring includes a C6-18 aromatic hydrocarbon ring and a C4-10 aromatic heterocyclic ring.
  • Specific C6-18 aromatic hydrocarbon rings include benzene ring, naphthalene ring, anthracene ring, phenanthrene ring, triphenylene ring, tetracene ring, indane ring, indene ring, fluorene ring and biphenyl ring.
  • a benzene ring, a naphthalene ring, a phenanthrene ring, and a fluorene ring are more preferable.
  • the C4-10 aromatic heterocyclic ring is preferably a 5- to 10-membered heterocyclic ring containing 1 to 3 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and specifically, pyrrole. ring, furan ring, thiophene ring, indole ring, benzofuran ring, benzothiophene ring, carbazole ring, pyrazole ring, indazole ring, imidazole ring, pyridine ring, quinoline ring, isoquinoline ring and the like.
  • a 5- to 8-membered heterocyclic ring containing 1 to 3 atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom as a heteroatom is preferable, and a pyrrole ring, a furan ring, a thiophene ring, an indole ring, and a benzofuran ring.
  • benzothiophene ring, carbazole ring, pyrazole ring and indazole ring are more preferred.
  • the aromatic ring of Ra may be substituted with 1 to 3 halogen atoms.
  • Rb represents a hydrogen atom, an aromatic ring optionally substituted with a halogen atom, or a group represented by the above formula (b).
  • q in the formula (b) represents an integer of 0-4. q is preferably 0 to 3, more preferably 1 to 3, even more preferably 1 to 2.
  • R 18 represents a hydrogen atom, an alkyl group or an aralkyl group
  • R 18 is preferably a hydrogen atom, a C1-10 alkyl group or a C7-20 aralkyl group.
  • alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl and hexyl groups.
  • Aralkyl groups include C7-16 aralkyl groups such as benzyl, 1-phenylethyl, 2-phenylethyl, 1-phenylpropyl, naphthylmethyl and 1-naphthylethyl groups.
  • q R 14 are each independently an aliphatic hydrocarbon group, an aliphatic hydrocarbon group substituted with an aliphatic hydrocarbon group via an oxygen atom, or an organic indicates a group.
  • R 16 represents a linear or branched alkylene group having 6 to 16 carbon atoms
  • R 17 is a hydrogen atom or an alkyl group having 1 to 4 carbon atoms
  • A represents either a silyl group or an alkyl group to which a silyloxy group is attached.
  • Examples of the organic group represented by R 14 include the same groups as those for R 12 above, and preferably the same groups as those for R 12 above.
  • R 13 represents a hydrogen atom, represents a single bond together with R 11 to form a fluorene ring together with ring A and ring B, or forms a xanthene ring together with ring A and ring B through an oxygen atom. may be formed.
  • Ring B in addition to q X 2 R 14 , further comprises a halogen atom, a C1-6 alkyl group optionally substituted with a halogen atom, and a C1-6 alkoxy group optionally substituted with a halogen atom may have a substituent selected from the group consisting of Halogen atoms include chlorine, fluorine, bromine and iodine atoms.
  • the C1-6 alkyl group optionally substituted with a halogen atom includes a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, a pentyl group and a hexyl group. , a dichloromethyl group, a trichloromethyl group, a trifluoromethyl group, and the like.
  • the C1-6 alkoxy group optionally substituted with a halogen atom includes a methoxy group, an ethoxy group, a propyloxy group, an isopropyloxy group, a butyloxy group, an isobutyloxy group, a sec-butyloxy group, a tert-butyloxy group, and a trichloromethoxy group. groups, trifluoromethoxy groups, and the like.
  • Y represents a hydroxy group, a thiol group, NHR 20 (R 20 represents a hydrogen atom, an alkyl group or an aralkyl group) or a halogen atom.
  • R 20 is preferably a hydrogen atom, a C1-10 alkyl group or a C7-20 aralkyl group.
  • alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl and hexyl groups.
  • Aralkyl groups include C7-16 aralkyl groups such as benzyl, 1-phenylethyl, 2-phenylethyl, 1-phenylpropyl, naphthylmethyl and 1-naphthylethyl groups.
  • Yb is --CH 2 OR 34 (wherein R 34 represents a hydrogen atom, a halogenocarbonyl group, an active ester carbonyl group or an active ester sulfonyl group), --CH 2 NHR 35 (wherein R 35 represents a hydrogen atom, a linear or branched alkyl group having 1 to 6 carbon atoms, or an aralkyl group), a halogenomethyl group, a formyl group, or an oxime, and R 21 , R 22 , R 23 , R 24 and at least one of R 25 represents a group represented by formula (8);
  • R 26 represents a linear or branched alkylene group having 6 to 16 carbon atoms
  • X 3 represents O or CONR 36 (wherein R 36 represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms);
  • A is represented by formula (9), (10), (11), (12), (13), (14), (15), (16), (17), (18) or (19) indicates a group.
  • R 27 , R 28 and R 29 are the same or different and represent a linear or branched alkyl group having 1 to 6 carbon atoms or an aryl group which may have a substituent; 30 represents a single bond or a linear or branched alkylene group having 1 to 3 carbon atoms, and R 31 , R 32 and R 33 each represent a linear or branched alkylene group having 1 to 3 carbon atoms.
  • the compound represented by formula (20) can be used as a carrier for liquid-phase peptide synthesis (Patent Documents 11, 12, 15).
  • R 51 represents a hydrogen atom, an active ester carbonyl group or an active ester sulfonyl group
  • R 51 represents a hydrogen atom, an active ester carbonyl group or an active ester sulfonyl group
  • —NHR 35 azide, halogen, isocyanate
  • X 5 is a hydrogen atom or a linear or branched alkyl or alkenyl group having 1 to 4 carbon atoms , or represents a cycloalkyl group
  • X 4 isocyanate
  • X 5 represents a linear or branched alkyl group or alkenyl group having 1 to 4 carbon atoms, or a cycloalkyl group
  • At least one of R 41 to R 50 represents a group represented by formula (2), and the remainder represents a hydrogen atom, a halogen atom, an alkyl group having 1 to 4 carbon atoms, or an
  • the compound represented by formula (21) can be used as a carrier for liquid-phase peptide synthesis (Patent Documents 13 and 14).
  • X 6 represents a hydroxy group or a halogen atom
  • at least one of R 61 to R 75 represents a group represented by formula (2), and the remainder are hydrogen atoms, halogen atoms, and 1 carbon atom.
  • 4 alkyl group or alkoxy group having 1 to 4 carbon atoms; may form
  • the carrier for liquid-phase peptide synthesis can also be bound via a linker to the carboxyl groups of amino acids, peptides, amino acid amides or peptide amides (such as amino acids) as raw materials.
  • the linker as used herein is an organic group having two reactive groups, one of which binds to the carboxyl group of the amino acid or the like, and the other of which binds to the carrier for liquid-phase peptide synthesis.
  • Preferred linkers are organic groups having a molecular weight of about 2000 or less (preferably about 1500 or less, more preferably about 1000 or less) and having reactive groups which may be the same or different, amino, carboxyl, and halomethyl groups. It is a compound having in the molecule at least two groups selected from the group consisting of For example, the following compounds can be mentioned.
  • Y is an integer of 1 to 6, preferably 1 to 4).
  • X is a halogen atom, preferably chlorine or bromine.
  • Z is an integer of 2 to 40, preferably 2 to 35, more preferably 2 to 28.
  • the structural formula of the above linker shows the state before binding to the side chain functional group or the like and the state before binding to the carrier for liquid-phase peptide synthesis).
  • the peptide extension reaction preferably has the following steps a, b and c.
  • the order of steps b and c is not critical, and the order of step b and then step c, that is, the organic solvent layer containing the condensate may be obtained after removing the protective group for the amino group, or step c and then step In the order of b, that is, after obtaining the organic solvent layer containing the condensate, the protective group for the amino group may be removed. a.
  • step a a step of obtaining an organic solvent layer containing;
  • step b a step of adding a dibenzofulvene trapping agent.
  • the amino acid, peptide, amino acid amide, or peptide amide bound to the carrier for liquid-phase peptide synthesis described in step a (hereinafter abbreviated as carrier-bound peptide for liquid-phase peptide synthesis) can be produced as follows. First, a carrier for liquid phase peptide synthesis is dissolved in an organic solvent such as THF, for example, an Fmoc-protected amino acid or peptide, a condensing agent such as N,N'-diisopropylcarbodiimide (DIPCI), and a base such as DMAP are added. to condense.
  • an organic solvent such as THF
  • a carrier-bound peptide for N-Fmoc-liquid phase synthesis which is an intermediate in which a carrier for liquid phase peptide synthesis is bound to the carboxyl group of an amino acid or peptide, can be produced.
  • the carrier for liquid-phase peptide synthesis is dissolved in an organic solvent such as toluene, and condensation is performed by adding, for example, an Fmoc-protected amino acid amide or peptide amide and an acid catalyst such as mesylic acid.
  • N-Fmoc-carrier-bound peptide for liquid phase synthesis which is an intermediate in which a carrier for liquid phase peptide synthesis is bound to the amide group of amino acid amide or peptide amide, can be produced.
  • amino-protected amino acid which is the other raw material
  • amino-protected amino acid is an amino acid or peptide whose amino group is protected with an amino-protecting group
  • carboxyl groups refer to amino acids or peptides that are unprotected and reactive.
  • amino-protecting groups include Fmoc group, Boc group, Cbz group, etc. Among them, Fmoc group, which can be deprotected under basic conditions, is more preferable.
  • amino group-protected amino acid has highly reactive functional groups such as hydroxyl, amino, guanidyl, carboxyl, thiol, indole, and imidazole groups
  • these functional groups are commonly used in peptide synthesis.
  • a protective group may be introduced, and the target compound can be obtained by removing the protective group as necessary at any point after the completion of the reaction.
  • hydroxyl-protecting groups include tBu, Trt, Bz (benzoyl), acetyl, and silyl groups
  • examples of guanidyl-protecting groups include Pbf, Boc, Pmc, and nitro groups.
  • carboxyl-protecting groups include tBu, methyl, ethyl, and Bz groups
  • examples of thiol-protecting groups include Trt, Acm (acetamidomethyl), tBu, and S-tBu ( dithio-tert-butyl) group, Dpm (diphenylmethyl) group, MBom (4-methoxybenzyloxymethyl) group and the like
  • examples of indole group-protecting groups include Boc group and the like
  • imidazole group-protecting group Examples include Boc group, Bom (benzyloxymethyl) group, Bum (tert-butoxymethyl) group, Trt group, Ddm (4,4'-dimethoxydiphenyl) group, MBom group and the like.
  • An amino group-protected amino acid can be produced, for example, by reacting an amino acid or peptide whose amino group is to be protected with an amino-protecting group with Fmoc-OSu or the like in a mixed solvent such as THF/water in the presence of a base. can be done.
  • the step a of the present invention is a step of condensing the raw materials, and the reaction solvent used in the step a is a solvent containing an organic solvent. If amino acids, peptides, amino acid amides or peptide amides are protected with the carrier for liquid-phase peptide synthesis used in the present invention, the obtained carrier-bound peptide for liquid-phase peptide synthesis becomes soluble in an organic solvent. Liquid phase peptide synthesis becomes possible.
  • organic solvents examples include THF, DMF, cyclohexane, CPME, 2-methylTHF, 4-methyltetrahydropyran (4-methylTHP), isopropyl acetate, chloroform, dichloromethane, N-methylpyrrolidone, dimethylacetamide ( DMAc) and NFM (N-formylmorpholine), preferably THF, DMF, CPME, 2-methylTHF, 4-methylTHP and N-methylpyrrolidone.
  • a mixed solvent of two or more of the above solvents may be used.
  • the condensation reaction is carried out by mixing the carrier for liquid phase peptide synthesis or the carrier-bound peptide for liquid phase peptide synthesis, the amino group-protected amino acid, the condensing agent and the base in a solvent containing the organic solvent. can be done.
  • the amount of the amino group-protected amino acid used relative to the carrier-bound peptide for liquid-phase peptide synthesis is generally 1.01-4 equivalents, preferably 1.03-3 equivalents, more preferably 1.03-3 equivalents, relative to the carrier-bound peptide for liquid-phase peptide synthesis. is 1.05 to 2 equivalents, more preferably 1.1 to 1.5 equivalents.
  • the unreacted amino acid active ester can be captured and inactivated by a quenching agent added thereafter. Therefore, even if an excess amino group-protected amino acid is used, the problem of residue does not occur.
  • Condensing agents commonly used in peptide synthesis can also be used in the present invention, such as 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)- 4-methylmorphonium chloride (DMT-MM), O-(benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), O-(7-azabenzo triazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU), O-(6-chlorobenzotriazol-1-yl)-1,1,3,3-tetramethyl Uronium hexafluorophosphate (HBTU(6-Cl)), O-(benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU), O-(6-chloro Benzotriazol-1-yl)-1,1,3,3-
  • DMT-MM, HBTU, HATU or COMU is preferred.
  • the amount of the condensing agent used is preferably 1 to 4 equivalents, more preferably 1 to 2 equivalents, still more preferably 1.05 to 1.45 equivalents, relative to the carrier-bound peptide for liquid-phase peptide synthesis.
  • Bases commonly used in peptide synthesis can also be used in the present invention. Examples include DIPEA (N,N-diisopropylethylamine), DMAP, NMM (N-methylmorpholine), TMP (2,4,6-trimethylpyridine). DIPEA is preferred.
  • an activator is preferably added in order to promote the reaction and suppress side reactions such as racemization.
  • the activating agent is a reagent that facilitates the formation of a peptide bond (amide bond) by leading an amino acid to a corresponding active ester, symmetrical acid anhydride, or the like in coexistence with a condensing agent.
  • an activator commonly used in peptide synthesis can be used.
  • 1-hydroxybenzotriazole HOBt
  • 1-hydroxy-1H-1,2,3-triazole ethyl carboxylate HCt
  • 1-hydroxy-7-azabenzotriazole HAt
  • 3-hydroxy-4- Ketobenzotriazine HOOBt
  • N-hydroxysuccinimide HSu
  • N-hydroxyphthalimide HPht
  • N-hydroxy-5-norbornene-2,3-dicarboximide HONb
  • pentafluorophenol cyano ( hydroxyimino)ethyl acetate (Oxyma) and the like.
  • Preferred are HOBt, HOOBt, HOCt, HOAt and Oxyma.
  • the amount of the activator used is preferably 1 to 4 equivalents, more preferably 1 to 2 equivalents, still more preferably 1.05 to 1.45 equivalents, relative to the carrier-bound peptide for liquid-phase peptide synthesis.
  • the amount of the solvent used is such that the concentration of the dissolved carrier-bound peptide for liquid-phase peptide synthesis is preferably 0.1 mM to 1M, more preferably 1 mM to 0.5M.
  • the reaction temperature is a temperature commonly used in peptide synthesis, for example, preferably -20 to 40°C, more preferably 0 to 30°C.
  • the condensation reaction time is usually 1 minute to 30 hours.
  • a step of adding an amino acid active ester quenching agent (hereinafter sometimes referred to as "quenching agent”) to the reaction solution after the condensation reaction may be performed.
  • an amino group-protected amino acid as a raw material is added in an excessive amount to the carrier for liquid phase peptide synthesis or the carrier-bound peptide for liquid phase peptide synthesis. Therefore, the amino acid active ester produced by activating the amino group-protected amino acid during the condensation reaction remains in excess after the condensation reaction.
  • the step of adding a quenching agent is a step of quenching this excess amino acid active ester.
  • the amount of the quenching agent to be added in this step is preferably 1 to 10 equivalents, more preferably 1 to 6 equivalents, still more preferably 1 to 3 equivalents, relative to 1 equivalent of the theoretically remaining active amino acid ester.
  • the amino acid active ester quenching agent is a compound having an amino group in the molecule, and is disclosed in Japanese Patent No. 6703668, Japanese Patent No. 6713983, International Publication No. 2021/132545, Molecules 2021, 26, 3497-3505. . and the like can be used.
  • quenching agents include hydroxylamine, amidosulfuric acid, hydroxylamine-O-sulfonic acid, hydroxylamine-O-phosphonic acid, alkylamines having primary or secondary amines, fragrances having primary or secondary amines.
  • Group amines can be used, and tertiary amines can also be used.
  • excess quenching agent can be removed to the aqueous layer by liquid-liquid separation, it is preferably water-soluble, and amines having hydrophilic substituents such as hydroxyl group, sulfo group, sulfate group and phosphoric acid group are preferred.
  • the number of amino groups in the compound may be one (monovalent), or may be bivalent or more.
  • alkylamines that can be used include alkylamines having 1 to 14 carbon atoms, preferably alkylamines having 2 to 10 carbon atoms, more preferably alkylamines having 2 to 8 carbon atoms, and still more preferably alkylamines having 2 to 8 carbon atoms. is an alkylamine having 3 to 4 carbon atoms.
  • aromatic amines examples include aromatic amines having 1 to 14 carbon atoms, preferably aromatic amines having 6 to 10 carbon atoms.
  • Specific amines include, but are not limited to, propylamine, methylamine, hexylamine, benzylamine, aniline, toluidine, 2,4,6-trimethylaniline, anisidine, phenetidine, hydroxylamine, 1-methyl Piperazine, 4-aminopiperidine, diethylenetriamine, triaminoethylamine, 1-ethylpiperazine, N,N-dimethylethylenediamine, ethylenediamine, piperazine, 2-(2-aminoethoxy)ethanol (AEE), taurine, 2-aminoethyl hydrogen sulfate (2-aminoethyl sulfate, AEHS) and the like.
  • NMI N-methylimidazole
  • DMAP dimethylamine
  • trimethylamine 2-(2-aminoethoxy)ethanol
  • AEE 2-(2-aminoethoxy)ethanol
  • taurine taurine
  • 2-aminoethyl hydrogen sulfate (2-aminoethyl sulfate, AEHS) are preferred.
  • Step b is a step of removing the amino-protecting group of the amino-protected amino acid in the reaction solution.
  • the step of removing the amino-protecting group differs depending on the type of amino-protecting group.
  • the amino-protecting group is an Fmoc group
  • the reaction solution should be made basic.
  • the amino-protecting group is a Boc group
  • the reaction solution may be subjected to acidic conditions.
  • the amino-protecting group is a Cbz group
  • catalytic reduction may be performed.
  • the step of removing the amino-protecting group when the amino-protecting group is an Fmoc group will be described.
  • the reaction solution can be made basic. .0]-5-nonene (DBN), 1,4-diazabicyclo[2.2.2]-octane (DABCO), triethylamine, tertiary amines such as tributylamine; 1-methylpiperazine, 4-aminopiperidine, Diethylenetriamine, triaminoethylamine, 1-ethylpiperazine, N,N-dimethylethylenediamine, ethylenediamine, piperidine, piperazine, etc.
  • Divalent or higher water-soluble amines having at least one primary or secondary amino group are used. be able to. DBU, DBN, piperidine, piperazine, 1-methylpiperazine, 4-aminopiperidine and diethylenetriamine are preferred, and DBU, piperidine, piperazine and 1-methylpiperazine are more preferred.
  • the equivalent of the amine compound added in step b is 1-30 equivalents, preferably 4-20 equivalents, more preferably 4-10 equivalents, relative to the amount of Fmoc groups present in the system.
  • a trapping agent for DBF dibenzofulvene
  • DBF-amine adduct an adduct of DBF and amine
  • Trapping agent a trapping agent for DBF (dibenzofulvene) produced by the de-Fmoc reaction and an adduct of DBF and amine (DBF-amine adduct)
  • DBF-amine adduct an adduct of DBF and amine
  • Trapping agent mercapto compounds.
  • the mercapto compound that can be used is not particularly limited as long as it has a mercapto group and the compound reacted with DBF exhibits water solubility.
  • carboxylic acids alkali metal salts of carboxylic acids, sulfonic acids, or mercapto compounds having one or more substituents selected from alkali metal salts of sulfonic acids, and represented by the following general formula (4) or (5) compounds represented.
  • L1 and L2 each represent a divalent organic group, and M represents a hydrogen atom or an alkali metal
  • L1 and L2 in general formula (4) or (5) each represent a divalent organic group.
  • the divalent organic group is preferably a divalent organic group having 1 to 10 carbon atoms, more preferably a linear or branched alkylene group having 1 to 10 carbon atoms and optionally having a mercapto group. , an arylene group having 6 to 10 carbon atoms which may have a mercapto group, and a heteroarylene group having 4 to 9 carbon atoms which may have a mercapto group.
  • M represents a hydrogen atom or an alkali metal. Specific examples include a hydrogen atom, sodium, and potassium.
  • 3-mercaptopropionic acid thiomalic acid, cysteine, sodium mercaptomethanesulfonate, sodium 2-mercaptoethanesulfonate, 2-mercaptoethanesulfonic acid, 3-mercaptopropanesulfonic acid, 3-mercaptopropanesulfonic acid sodium, 1,3-dimercaptopropanesulfonic acid, sodium 2-mercaptobenzimidazole-5-sulfonate, and the like, with 3-mercaptopropanesulfonic acid being preferred.
  • the amount of the mercapto compound added is preferably 1 to 30 equivalents, more preferably 1 to 10 equivalents, even more preferably 1 to 5 equivalents, relative to the amount of the Fmoc group.
  • the amine compound and the mercapto compound may be added simultaneously, or the mercapto compound and then the amine compound may be added in this order.
  • the Fmoc elimination step may be performed at a temperature of ⁇ 20 to 40° C. for 1 minute to 5 hours.
  • step c an aqueous solution is added to the reaction solution, followed by liquid separation to produce an amino acid, peptide, amino acid amide or peptide amide bound to the carrier for liquid phase peptide synthesis and the amino acid or peptide from which the amino protecting group has been removed.
  • step b is a step of obtaining an organic solvent layer containing a condensate of After adding the aqueous solution to the reaction solution in step b, the aqueous layer and the organic solvent layer are separated.
  • the aqueous layer contains a condensate of an amino acid or peptide from which the amino protecting group has been removed and an active ester quenching agent and a DBF-trapping agent adduct. That is, the condensate of the amino acid or peptide from which the amino protecting group has been removed and the active ester quenching agent is easily extracted into the aqueous layer only by adding the aqueous solution in step c.
  • the organic solvent layer contains a condensate of an amino acid, peptide, amino acid amide or peptide amide bound to a carrier for liquid-phase peptide synthesis and an amino acid or peptide from which the amino protecting group has been removed.
  • the aqueous solution used here includes water or an aqueous solution having a pH in the vicinity of neutral to basic.
  • examples include an aqueous solution, an aqueous sodium hydrogencarbonate solution, an aqueous potassium hydrogencarbonate solution, an aqueous dipotassium hydrogenphosphate solution, an aqueous tripotassium phosphate solution, or a mixed solvent of these aqueous solutions and DMF, DMSO, NFM, or NMP.
  • the resulting Ganirelix is optionally converted into organic acid salts such as acetates, formates, oxalates, succinates and trifluoroacetates, mineral salts such as hydrochlorides, nitrates, sulfates and phosphates. can be converted to
  • Fmoc-hArg(Et) 2 (Boc) 2 -OH represents a mixture of three isomers in the reaction formula. Therefore, H-hArg(Et) 2 (Boc) 2 -Pro-D-Ala-NH(D2-STag) is also presumed to be a mixture of three isomers.
  • Ac-D-Nal(2)-D-pClPhe-D-Pal(3)-Ser(tBu)-Tyr(tBu)-D -hArg(Et) 2 (Boc) 2 -Leu-hArg(Et) 2 (Boc) 2 -Pro-D-Ala-NH(D2-STag) is the combination of hArg(Et) 2 (Boc) 2 and D-hArg (Et) 2 (Boc) 2 is presumed to be each of the three isomers in the reaction formula, possibly resulting in a mixture of nine isomers in total. )
  • * in the structure of R' indicates a binding
  • Example (1-a) 2.00 g (1.83 mmol) of Fmoc-NH(D2-STag) was dissolved in 29.3 mL of cyclopentyl methyl ether (CPME), 7.33 mL of DMF, and 3-mercapto- dissolved in 2.55 mL of dimethylsulfoxide (DMSO).
  • CPME cyclopentyl methyl ether
  • DMF dimethylsulfoxide
  • AEE 2-(2-Aminoethoxy)ethanol
  • Example (1-c) To the resulting mixture, CPME 2.20 mL, DMF 8.30 mL, Fmoc-Pro-OH.H 2 O 0.782 g (2.20 mmol), DIPEA 1.28 mL (7.33 mmol), COMU 0.942 g ( 2.20 mmol) was added and stirred at room temperature for 50 minutes. 44.0 ⁇ L (0.444 mmol) of AEE was added, and the mixture was stirred at room temperature for 15 minutes.
  • Example (1-f) 0.800 mL of CPME, 8.95 mL of DMF, 1.28 mL (7.33 mmol) of DIPEA, 0.126 mL (2.20 mmol) of acetic acid, and 0.942 g (2.20 mmol) of COMU were added to the resulting mixture, and the mixture was cooled to room temperature. and stirred for 50 minutes. The reaction solution was concentrated under reduced pressure, and the resulting residue was added dropwise to 106 mL of acetonitrile (MeCN). Collect the solids by filtration and wash the filter cake with 50.0 mL of MeCN.
  • MeCN acetonitrile
  • Example (1-g) A mixed solution of 13.9 mL (181 mmol) of trifluoroacetic acid, 0.365 mL (1.78 mmol) of Triisopropylsilane, and 0.365 mL (20.3 mmol) of water was cooled to 5° C., and Ac-D-Nal(2)-D- pClPhe-D-Pal(3)-Ser(tBu)-Tyr(tBu)-D-hArg(Et) 2 (Boc) 2 -Leu-hArg(Et) 2 (Boc) 2 -Pro-D-Ala-NH (D2-STag) 1.50 g was added.
  • Comparative examples (a), (b), (c) H-Pro-D-Ala-NH(D2-STag) was prepared from 2.00 g (1.83 mmol) of Fmoc-NH(D2-STag) in the same manner as in Examples 1-a, 1-b, and 1-c.
  • Example (2-a) A mixed solution containing NH 2 (D2-STag) was obtained from 0.800 g (0.733 mmol) of Fmoc-NH(D2-STag) in the same manner as in Example (1-a).
  • Example (2-b) 0.600 mL of CPME, 3.30 mL of DMF, 0.290 g (0.880 mmol) of Fmoc-D-Ala-OH.H 2 O, 0.511 mL (2.93 mmol) of DIPEA, and 0.511 mL of DIPEA were added to the resulting mixture. 377 g (0.880 mmol) was added and stirred at room temperature for 50 minutes. 24.8 mg (0.176 mmol) of 2-AEHS dissolved in 0.704 mL of DMSO was added and stirred at room temperature for 15 minutes.
  • Example (2-c) To the resulting mixture, CPME 0.800 mL, DMF 3.30 mL, Fmoc-Pro-OH.H 2 O 0.313 g (0.880 mmol), DIPEA 0.511 mL (2.93 mmol), COMU 0.377 g ( 0.880 mmol) was added and stirred at room temperature for 50 minutes. 24.8 mg (0.176 mmol) of 2-AEHS dissolved in 0.704 mL of DMSO was added and stirred at room temperature for 15 minutes.
  • Example (2-d) 0.600 mL of CPME, 3.30 mL of DMF, and 0.587 g of Fmoc-hArg(Et) 2 (Boc) 2 -OH (a mixture of three isomers shown in the figure) (0.587 g) were added to the resulting mixture. 880 mmol), 0.511 mL (2.93 mmol) of DIPEA, and 0.377 g (0.880 mmol) of COMU were added and stirred at room temperature for 50 minutes. 24.8 mg (0.176 mmol) of 2-AEHS dissolved in 0.704 mL of DMSO was added and stirred at room temperature for 15 minutes.
  • Example (2-e) Similar to Example (2-d), Fmoc-Leu-OH, Fmoc-D-hArg(Et) 2 (Boc) 2 -OH, Fmoc-Tyr(tBu)-OH, Fmoc-Ser(tBu)-OH , Fmoc-D-Pal(3)-OH, Fmoc-D-pClPhe-OH, Fmoc-D-Nal(2)-OH and HD-Nal(2)-D-pClPhe -D-Pal(3)-Ser(tBu)-Tyr(tBu)-D-hArg(Et) 2 (Boc) 2- Leu-hArg(Et) 2 (Boc) 2 -Pro-D-Ala-NH( A mixed solution containing D2-STag) was obtained.
  • Example (2-g) Ac-D-Nal(2)-D-pClPhe-D-Pal(3)-Ser(tBu)-Tyr(tBu)-D-hArg(Et) 2 in the same manner as in Example (1-g) (Boc) 2 -Leu-hArg(Et) 2 (Boc) 2 -Pro-D-Ala-NH(D2-STag) from 0.700 g of Ac-D-Nal(2)-D-pClPhe-D-Pal( 3) 0.455 g of -Ser-Tyr-D-hArg(Et) 2 -Leu-hArg(Et) 2 -Pro-D-Ala-NH 2 ⁇ nTFA was obtained.
  • ESIMS (m/z) 785.5 (M+2H) ⁇ 2+> HPLC Purity: 94.4% HPLC analysis conditions: same as (2) in Example (1-g).
  • the Boc-protected Fmoc-hArg(Et) 2 ( Boc) 2 -OH of the present invention was used in place of the conventional proton-protected Fmoc-hArg(Et) 2 -OH ⁇ HCl. It was found that by using it, the liquid separation property is improved, and ganirelix can be obtained by an industrially advantageous method.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne un nouveau procédé pour la production de ganirélix par un procédé de synthèse peptidique en phase liquide.　La présente invention porte sur un procédé qui sert à la production de ganirélix ou d'un sel de celui-ci par un procédé de synthèse peptidique en phase liquide et qui utilise un produit de liaison entre un composé représenté par les formules (1)-(3) (où R1 et R2 représentent chacun Boc, Cbz, Troc, Alloc, Trt, Mmt, Teoc, Phth, SES ou ivDde et R3 représente un groupe protecteur d'amino) et un support pour la synthèse peptidique en phase liquide, en tant que matière première pour une réaction de condensation des troisième et cinquième restes de diéthyl homoarginine à partir de l'extrémité C-terminale.
PCT/JP2022/032700 2021-09-01 2022-08-31 Procédé pour la production de ganirélix ou d'un sel de celui-ci WO2023033017A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021142162A JP2025001050A (ja) 2021-09-01 2021-09-01 ガニレリクス又はその塩の製造法
JP2021-142162 2021-09-01

Publications (1)

Publication Number Publication Date
WO2023033017A1 true WO2023033017A1 (fr) 2023-03-09

Family

ID=85411319

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/032700 WO2023033017A1 (fr) 2021-09-01 2022-08-31 Procédé pour la production de ganirélix ou d'un sel de celui-ci

Country Status (3)

Country Link
JP (1) JP2025001050A (fr)
TW (1) TW202328164A (fr)
WO (1) WO2023033017A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024071178A1 (fr) * 2022-09-28 2024-04-04 積水メディカル株式会社 Procédé de production d'un composé benzylamine à substitution alkylsilyloxy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102584945A (zh) * 2012-02-09 2012-07-18 深圳翰宇药业股份有限公司 一种醋酸加尼瑞克的制备方法
CN104844694A (zh) * 2014-02-17 2015-08-19 深圳翰宇药业股份有限公司 一种醋酸加尼瑞克的制备方法
JP2017521487A (ja) * 2013-06-18 2017-08-03 深▲せん▼翰宇薬業股▲ふん▼有限公司Ｈｙｂｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． ガニレリクス前駆体、及びそれを用いた酢酸ガニレリクスの製造方法
WO2019198833A1 (fr) * 2018-04-13 2019-10-17 Jitsubo株式会社 Procédé de synthèse peptidique

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102584945A (zh) * 2012-02-09 2012-07-18 深圳翰宇药业股份有限公司 一种醋酸加尼瑞克的制备方法
JP2017521487A (ja) * 2013-06-18 2017-08-03 深▲せん▼翰宇薬業股▲ふん▼有限公司Ｈｙｂｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． ガニレリクス前駆体、及びそれを用いた酢酸ガニレリクスの製造方法
CN104844694A (zh) * 2014-02-17 2015-08-19 深圳翰宇药业股份有限公司 一种醋酸加尼瑞克的制备方法
WO2019198833A1 (fr) * 2018-04-13 2019-10-17 Jitsubo株式会社 Procédé de synthèse peptidique

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024071178A1 (fr) * 2022-09-28 2024-04-04 積水メディカル株式会社 Procédé de production d'un composé benzylamine à substitution alkylsilyloxy

Also Published As

Publication number Publication date
JP2025001050A (ja) 2025-01-08
TW202328164A (zh) 2023-07-16

Similar Documents

Publication Publication Date Title
JP6703668B2 (ja) ペプチド合成方法
JP7063408B1 (ja) 液相ペプチド製造方法
JP6703669B2 (ja) リュープロレリンの製造方法
TWI866995B (zh) 肽化合物的製造方法、保護基形成用試藥及縮合多環芳香族烴化合物
JP7063409B1 (ja) Ｆｍоｃ基を除去する方法
Monfregola et al. Synthetic strategy for side chain mono-N-alkylation of Fmoc-amino acids promoted by molecular sieves
WO2023033017A1 (fr) Procédé pour la production de ganirélix ou d'un sel de celui-ci
US20180282367A1 (en) New methods for making barusiban and its intermediates
AU596899B2 (en) Guanidine-related compounds comprising a substituted tetraphenylborate ion, process for obtaining these compounds, and use of the compounds
JP5445456B2 (ja) ジベンゾフルベンの除去方法
JP5985534B2 (ja) グアニジル基およびアミノ基の保護のためのインドールスルホニル保護基
TWI860373B (zh) 肽化合物的製造方法、保護基形成用試藥及縮合多環化合物
EP3713950A1 (fr) Procédé de préparation de peptides
JP2017537875A (ja) ペプチドを合成する方法およびペプチドを固相合成する方法を実施するための装置
JP7154513B1 (ja) 液相ペプチド製造方法
IE67453B1 (en) Process for the solubilization of peptides and process for peptide synthesis
WO2023033016A1 (fr) Dérivé d'arginine
TW202233574A (zh) 肽之製造方法、保護基形成用試藥及縮合多環化合物
JP7162853B1 (ja) 液相ペプチド合成用担体結合ペプチドの分析方法
CN116997559A (zh) 氨基酸或肽的制造方法、保护基形成用试剂及化合物
CN117500817A (zh) 包含磷酰胆碱缀合物的肽及其合成方法
CN119080882A (zh) 一种依替巴肽衍生物及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22864599

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22864599

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载